Evommune is focused on developing innovative therapies aimed at treating chronic inflammatory diseases by targeting the underlying causes of inflammation. Their lead candidate, EVO756, is a highly selective MRGPRX2 antagonist designed for patients suffering from chronic spontaneous urticaria and chronic inducible urticaria. The company has made significant progress in its clinical trials, including a Phase 1 trial that demonstrated positive proof-of-concept results for EVO756, and they are currently advancing into Phase 2 trials to further evaluate its safety and efficacy.

In addition to EVO756, Evommune is exploring other therapeutic candidates, including EVO301, which targets IL-18 for atopic dermatitis, and a PKCϴ inhibitor aimed at inflammatory bowel disease. The company is committed to evolving immunology by developing a diverse pipeline of programs that address various inflammatory conditions with clear unmet medical needs. Their approach emphasizes the modulation of mast cell and T-cell activity, which holds promise for improving outcomes in multiple patient populations affected by chronic inflammatory diseases.

United States

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.

Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.

Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.

Evommune

Company Details